Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 19/20 | 1.00 |
| ▸ | AR | P10275 | 8/20 | 0.78 |
| ▸ | CBR1 | P16152 | 6/20 | 0.78 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.72 |
| ▸ | DNM2 | P50570 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11070985 | 0.76 | SRC (0.83) | AKR1C3 | |
| SCHEMBL4570242 | 0.76 | DNM2 (1.00) | AKR1C3ARCBR1AKR1C1DNM2 | |
| SCHEMBL2760104 | 0.76 | SRC (0.68) | AKR1C3 | |
| SCHEMBL4372468 | 0.74 | P2RX1 (0.71) | AKR1C3 | |
| SCHEMBL28771223 | 0.73 | TERT (0.84) | AKR1C3 | |
| SCHEMBL2735971 | 0.71 | SRC (1.00) | AKR1C3 | |
| SCHEMBL216822 | 0.71 | NPC1 (1.00) | AKR1C3 | |
| SCHEMBL8837282 | 0.71 | NPC1 (0.82) | AKR1C3ARCBR1AKR1C1 | |
| SCHEMBL9806526 | 0.71 | KMT2A (0.66) | AKR1C3 | |
| SCHEMBL982797 | 0.69 | AKR1C3 (0.59) | AKR1C3ARCBR1AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088768-B2 | Protein kinase and phosphatase inhibitors | THE RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK (US) | 2012-01-03 | — | — | US | disclosed |
| US-20110136807-A1 | Bicyclic compositions and methods for modulating a kinase cascade | KINEX PHARMACEUTICALS, LLC (US) | 2011-06-09 | — | — | US | disclosed |
| US-7901894-B2 | Kinase inhibitors | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2011-03-08 | — | — | US | disclosed |
| US-7901894-B2 | Kinase inhibitors | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2011-03-08 | — | — | US | disclosed |
| US-20110028474-A1 | PROTEIN KINASE AND PHOSPHATASE INHIBITORS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2011-02-03 | — | — | US | disclosed |
| EP-1147214-B1 | A NOVEL METHOD FOR DESIGNING PROTEIN KINASE INHIBITORS | UNIV NEW YORK STATE RES FOUND (US) | 2011-01-05 | — | — | EP | disclosed |
| US-7838542-B2 | Bicyclic compositions and methods for modulating a kinase cascade | KINEX PHARMACEUTICALS, LLC (US) | 2010-11-23 | — | — | US | disclosed |
| US-7838542-B2 | Bicyclic compositions and methods for modulating a kinase cascade | KINEX PHARMACEUTICALS, LLC (US) | 2010-11-23 | — | — | US | disclosed |
| US-7772216-B2 | Protein kinase and phosphatase inhibitors and methods for designing them | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772216-B2 | Protein kinase and phosphatase inhibitors and methods for designing them | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2010-08-10 | — | — | US | disclosed |
| US-20080004241-A1 | 2-carboxamide substituted indoles; osteoporosis, hepatitis B, ophthalmic disease, diabetes, atherosclerosis, obesity, chronic neuropathic pain, stroke; protein tyrosine kinase (PTK) inhibitors; 5-fluoro-3-phenylindole-2-carboxamides | OAKTREE FUND ADMINISTRATION, LLC | 2008-01-03 | — | — | US | disclosed |
| US-20080004241-A1 | 2-carboxamide substituted indoles; osteoporosis, hepatitis B, ophthalmic disease, diabetes, atherosclerosis, obesity, chronic neuropathic pain, stroke; protein tyrosine kinase (PTK) inhibitors; 5-fluoro-3-phenylindole-2-carboxamides | OAKTREE FUND ADMINISTRATION, LLC | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028474-A1 | PROTEIN KINASE AND PHOSPHATASE INHIBITORS | PTPN5, PTPN2, PTPN4 | AKR1C3 2463/4885AR 3074/4885CBR1 3602/4885 |
| US-20080004241-A1 | 2-carboxamide substituted indoles; osteoporosis, hepatitis B, ophthalmic disease, diabetes, atherosclerosis, obesity, chronic neuropathic pain, stroke; protein tyrosine kinase (PTK) inhibitors; 5-fluoro-3-phenylindole-2-carboxamides | PTK2B, GRK2, FRK | AKR1C3 2679/4885AR 1309/4885CBR1 3160/4885 |
| US-20110136807-A1 | Bicyclic compositions and methods for modulating a kinase cascade | MAP3K20, MAP3K6, MAP3K2 | AKR1C3 2550/4885AR 1691/4885CBR1 2373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.